Margin trading increases the risk of loss and clients’ losses may exceed the deposits placed. The value of securities may fluctuate and as a result, clients may lose more than their original investment.
Tools provided by Webull may provide general analysis upon your input but shall not be construed as providing investment advice or recommendation.Īll investments involve risks and are not suitable for every investor.
Adium pharma s.a professional#
Please seek advice from a professional financial adviser regarding the suitability of the investment product before investing. Services are only intended for persons in jurisdictions or countries where it is legal for such persons to receive them.Īny advice or recommendation is intended for general circulation and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. Investors should be aware that system response, execution price, speed, liquidity, market data, and account access times are affected by many factors, including market volatility, size and type of order, market conditions, system performance and other factors.ĭistribution of investment products to, or services offered to, any person is not intended in any jurisdiction where such distribution or use would contravene prevailing laws or regulations. Webull Securities accepts legal responsibility for the contents of such research analysis or report only to the extent as required by law, except if the research analysis or report is issued or promulgated to a person who is an accredited investor, an expert investor, or an institutional investor, as defined in the Securities and Futures Act 2001. Customers can contact Webull Securities in respect of any Data matters pertaining to research analysis or report. Data disclaimers are set forth in the Webull Data Disclaimer. Information provided is for informational purposes only, unless otherwise stated. No content on this website/application or affiliated websites/applications shall be considered as a recommendation or solicitation for the purchase or sale of securities, derivatives or any other investment products.Īll information and data (collectively “Data”) on this website/application are for reference only and no historical data should be considered as the basis for predicting future trends. The content on Webull’s website/application may contain advertisements, and the advertisement has not been reviewed by the Monetary Authority of Singapore. Webull and Webull Securities are separate entities under common ownership. (“Webull Securities”) (UEN: 202116981M), a Capital Markets Services Licence holder under the Securities and Futures Act 2001, licensed and regulated by the Monetary Authority of Singapore. (“Webull”).įinancial products and services are offered to self-directed customers by Webull Securities (Singapore) Pte.
The company last week said it was developing three new vaccines based on the same messenger RNA (mRNA) technology used for its COVID-19 shot, including one for viral infection shingles.Įarlier, Moderna also announced a partnership with Adium Pharma SA for the distribution of its vaccine in Latin America.Market data, development and operations of Webull’s website/application are provided by Webull Technologies Pte.
Adium pharma s.a full#
Moderna’s vaccine received full US approval in January for adults and is cleared for use in more than 70 countries. Thermo Fisher had already partnered with Moderna last year to help scale up production of its COVID vaccine, branded as Spikevax.Īs a part of the 15-year expanded deal, Thermo Fisher would provide dedicated manufacturing capacity in the US for fill/finish services as well as labelling and packaging services for Spikevax and other mRNA drugs in Moderna’s pipeline.
Moderna Inc has entered into a long-term agreement with Thermo Fisher Scientific for the manufacturing of its COVID-19 vaccine and other experimental medicines based on mRNA technology, the companies said recently.
0 kommentar(er)
